Treatment with (R)-albuterol has no advantage over racemic albuterol.

70. Truitt T, Witko J, Halpern M. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. Chest 2003;123:128–135. 71. Skoner DP, Greos LS, Kim LT, Roach JM, Parsey M, Baumgartner RA. Evaluation of the safety and efficacy of levalbuterol in 2–5-year-old patients with asthma. Pediatr Pulmonol 2005;40:477–486. 72. Nelson HS, Bensch G, Pleskow WW, DiSantostefano R, DeGraw S, Reasner DS, Rollins TE, Rubin PD. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998;102:943–952. 73. Gawchik SM, Saccur CL, Noonan M, Reasner DS, DeGraw SS. The safety and efficacy of nebulized levalbuterol compared to racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 1999;103:615–621. 74. Handley DA, Tinkelman D, Noonan M, Rollins TE, Snider ME, Caron J. Dose–response evaluation of levalbuterol versus racemic albuterol in patients with asthma. J Asthma 2000;37:319–327. 75. Milgrom H, Skoner DP, Bensch G, Kim KT, Klaus R, Baumgartner RA. Low dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol 2001;108:939–945. 76. Pleskow WW, Nelson HS, Schaefer K, Claus R, Roach JM. Pairwise comparison of levalbuterol versus racemic albuterol in the treatment of moderate-to-severe asthma. Allergy Asthma Proc 2004;25:429–436. 77. Schreck DM, Babin S. Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED. Am J Emerg Med 2005; 23:842–847. 78. Asmus MJ, Hendeles L. Levalbuterol nebulizer solution: is it worth five times the cost of albuterol? Pharmacotherapy 2000;20:123–129. 79. Ahrens R, Weinberger M. Levalbuterol and racemic albuterol: are there therapeutic differences? J Allergy Clin Immunol 2001;108:681–684. 80. Asmus MJ, Hendeles L, Weinberger M, Ahrens RC, Bisgaard H, Lotvall J, O’Byrne PM, Cockroft DW. Levalbuterol has not been established to have therapeutic advantage over racemic albuterol. J Allergy Clin Immunol 2002;110:325. 81. Boulton DW, Fawcett JP. Beta 2-agonist eutomers: a rational option for the treatment of asthma? Am J Respir Med 2002;1:305–311. 82. Mansfield P, Henry D, Tonkin A. Single-enantiomer drugs: elegant science, disappointing effects. Clin Pharmacokinet 2004;43:287–290. 83. Berger WE. Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma. Ann Allergy Asthma Immunol 2003;91:587–588.